Status:
COMPLETED
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of BMS-779788 in healthy subjects
Eligibility Criteria
Inclusion
- Men and women (not of child bearing potential) ages 18 to 45
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Exclusion
- Women of child bearing potential
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00836602
Start Date
February 1 2009
End Date
July 1 2009
Last Update
February 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Heidelberg, Victoria, Australia, 3084